JP2012509259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509259A5 JP2012509259A5 JP2011536365A JP2011536365A JP2012509259A5 JP 2012509259 A5 JP2012509259 A5 JP 2012509259A5 JP 2011536365 A JP2011536365 A JP 2011536365A JP 2011536365 A JP2011536365 A JP 2011536365A JP 2012509259 A5 JP2012509259 A5 JP 2012509259A5
- Authority
- JP
- Japan
- Prior art keywords
- hsa linker
- seq
- composition
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 64
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 229960000575 trastuzumab Drugs 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 229960003668 docetaxel Drugs 0.000 claims description 5
- 229960003881 letrozole Drugs 0.000 claims description 5
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229940123237 Taxane Drugs 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 4
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- OPQNCARIZFLNLF-UHFFFAOYSA-N ansamitocin P-3 Natural products CN1C(=O)CC(OC(=O)C(C)C)C2(C)OC2C(C)C(OC(=O)N2)CC2(O)C(OC)C=CC=C(C)CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-UHFFFAOYSA-N 0.000 claims description 3
- OPQNCARIZFLNLF-JBHFWYGFSA-N ansamitocin P3 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)C(C)C)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 OPQNCARIZFLNLF-JBHFWYGFSA-N 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960002087 pertuzumab Drugs 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960001603 tamoxifen Drugs 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 241000699660 Mus musculus Species 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000011580 nude mouse model Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 201000000292 clear cell sarcoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11579708P | 2008-11-18 | 2008-11-18 | |
| US61/115,797 | 2008-11-18 | ||
| USPCT/US2009/040259 | 2009-04-10 | ||
| PCT/US2009/040259 WO2009126920A2 (en) | 2008-04-11 | 2009-04-10 | Human serum albumin linkers and conjugates thereof |
| PCT/US2009/060721 WO2010059315A1 (en) | 2008-11-18 | 2009-10-14 | Human serum albumin linkers and conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509259A JP2012509259A (ja) | 2012-04-19 |
| JP2012509259A5 true JP2012509259A5 (index.php) | 2013-05-23 |
| JP5677972B2 JP5677972B2 (ja) | 2015-02-25 |
Family
ID=42198443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536365A Expired - Fee Related JP5677972B2 (ja) | 2008-11-18 | 2009-10-14 | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8927694B2 (index.php) |
| JP (1) | JP5677972B2 (index.php) |
| KR (1) | KR20110112301A (index.php) |
| CN (1) | CN102282168A (index.php) |
| BR (1) | BRPI0921586A2 (index.php) |
| WO (1) | WO2010059315A1 (index.php) |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| EP2091975A4 (en) * | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
| EP2129396B1 (en) | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| US12529164B2 (en) | 2007-09-14 | 2026-01-20 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA3187687A1 (en) | 2007-09-14 | 2009-03-19 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8927694B2 (en) | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| CN102573922B (zh) | 2009-08-17 | 2015-08-05 | 罗切格利卡特公司 | 靶向性免疫缀合物 |
| ES2700230T3 (es) * | 2009-10-30 | 2019-02-14 | Albumedix Ltd | Variantes de albúmina |
| ES2678144T3 (es) | 2010-02-16 | 2018-08-09 | Medimmune, Llc | Composiciones relacionadas con SAH y métodos de uso |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| WO2011139681A1 (en) | 2010-04-26 | 2011-11-10 | Merrimack Pharmaceuticals | Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug |
| WO2011138392A1 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies |
| SG185415A1 (en) | 2010-05-06 | 2012-12-28 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
| FI3434767T3 (fi) | 2010-11-30 | 2026-02-12 | Chugai Seiyaku Kk | Sytotoksisuutta aiheuttava terapeuttinen aine |
| EP2648738A2 (en) | 2010-12-06 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
| EP3778642A1 (en) * | 2010-12-27 | 2021-02-17 | Apo-T B.V. | A polypeptide that binds aberrant cells and induces apoptosis |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| KR20140053865A (ko) * | 2011-02-24 | 2014-05-08 | 메리맥 파마슈티컬즈, 인크. | 항-ｅｒｂｂ3제를 포함하는 조합 요법 |
| CA2828811C (en) | 2011-03-03 | 2021-09-21 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| CN103562226A (zh) * | 2011-03-11 | 2014-02-05 | 梅里麦克制药股份有限公司 | 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌 |
| JP2014509593A (ja) | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
| JP6430828B2 (ja) | 2011-05-05 | 2018-11-28 | アルブミディクス リミティド | アルブミン変異体 |
| WO2013048243A1 (en) | 2011-09-29 | 2013-04-04 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| JP2015502741A (ja) * | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| HUE056462T2 (hu) | 2011-11-04 | 2022-02-28 | Zymeworks Inc | Stabil heterodimer antestest tervezés mutációkkal az FC domainben |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| US20130165628A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double Binding Constructs |
| WO2013096939A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Selective binding compounds |
| JP2015504895A (ja) | 2012-01-13 | 2015-02-16 | エーピーオー‐ティー ビー．ヴイ． | 毒性部分を備える異常細胞拘束性免疫グロブリン |
| US20150011736A1 (en) * | 2012-01-20 | 2015-01-08 | Sea Lane Biotechnologies, Llc | Binding molecule conjugates |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| CN104755497A (zh) * | 2012-05-11 | 2015-07-01 | 梅里麦克制药股份有限公司 | 结合抗癌治疗剂的双特异性scfv轭合物的剂量和给药 |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| WO2014004586A1 (en) | 2012-06-25 | 2014-01-03 | Zymeworks Inc. | Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| CA2878640C (en) | 2012-07-13 | 2023-10-24 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| RU2670063C2 (ru) | 2012-11-08 | 2018-10-17 | Альбумедикс А/С | Варианты альбумина |
| US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
| JP2016501234A (ja) | 2012-12-03 | 2016-01-18 | メリマック ファーマスーティカルズ, インコーポレイテッドMerrimack Pharmaceuticals, Inc. | Ｈｅｒ２陽性癌を処置するための併用療法 |
| WO2014098464A1 (ko) * | 2012-12-18 | 2014-06-26 | 이화여자대학교 산학협력단 | 인간혈청알부민 열안정화용 조성물 및 이를 이용한 열안정화된 인간혈청알부민의 제조방법 |
| WO2014121033A1 (en) * | 2013-02-04 | 2014-08-07 | Fl Therapeutics Llc | Soluble complexes of drug analogs and albumin |
| CA2908198A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| EP2994164B1 (en) | 2013-05-08 | 2020-08-05 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| EP3001813B1 (en) | 2013-05-13 | 2019-03-27 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| CA2913363A1 (en) * | 2013-05-24 | 2014-11-27 | Zymeworks Inc. | Modular protein drug conjugate therapeutic |
| ES2688206T3 (es) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedimiento de evaluación de la identidad y la estabilidad de proteínas |
| JP6509867B2 (ja) | 2013-08-30 | 2019-05-08 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害を治療するためにインターロイキン−１０を使用する方法 |
| EP3052129A2 (en) | 2013-09-30 | 2016-08-10 | Daiichi Sankyo Company, Limited | Protein biomarker and uses thereof |
| WO2015070060A1 (en) | 2013-11-11 | 2015-05-14 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN111228510B (zh) | 2013-12-25 | 2024-06-18 | 第一三共株式会社 | 抗trop2抗体-药物偶联物 |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10487140B2 (en) | 2014-01-14 | 2019-11-26 | Integrated Biotherapeutics, Inc. | Targeting immunological functions to the site of bacterial infections using cell wall targeting domains of bacteriolysins |
| EP3973995A1 (en) | 2014-01-31 | 2022-03-30 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| LT3110849T (lt) * | 2014-02-28 | 2020-12-10 | Merus N.V. | Antikūnai, surišantys erbb-2 ir erbb-3 |
| TWI726842B (zh) * | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
| WO2015155976A1 (ja) * | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| US11473080B2 (en) * | 2014-04-30 | 2022-10-18 | The Board Of Trustees Of The University Of Illinois | Method for generating high affinity, bivalent binding agents for sandwich assays |
| SG11201609370QA (en) | 2014-05-13 | 2016-12-29 | Chugai Pharmaceutical Co Ltd | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
| JP6695812B2 (ja) | 2014-05-14 | 2020-05-20 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ３のベータヘアピン及びｈｅｒ２のドメインｉｉに結合するｈｅｒ３／ｈｅｒ２二重特異性抗体 |
| US9937259B2 (en) | 2014-06-27 | 2018-04-10 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivatives and non-covalent complexes with albumin |
| US20160045596A1 (en) | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
| GB201417067D0 (en) * | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| WO2016070045A1 (en) * | 2014-10-31 | 2016-05-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tlr9 targeted cytotoxic agents |
| EP3242682A1 (en) | 2015-01-08 | 2017-11-15 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| US20160361415A1 (en) | 2015-05-28 | 2016-12-15 | Armo Biosciences, Inc. | Methods of Using Interleukin-10 for Treating Diseases and Disorders |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| ES2938186T3 (es) | 2015-06-29 | 2023-04-05 | Daiichi Sankyo Co Ltd | Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco |
| MX395317B (es) | 2015-07-15 | 2025-03-25 | Genmab As | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. |
| CN112263683A (zh) * | 2015-08-11 | 2021-01-26 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| KR20180037210A (ko) | 2015-08-20 | 2018-04-11 | 입센 바이오팜 리미티드 | 암 치료를 위한 리포좀 이리노테칸 및 parp 저해제를 이용하는 조합요법 |
| TW202126293A (zh) | 2015-08-21 | 2021-07-16 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| EP4606387A3 (en) | 2015-08-25 | 2025-11-19 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| WO2017053170A1 (en) * | 2015-09-24 | 2017-03-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| EP3355907B1 (en) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| JP6941606B2 (ja) | 2015-10-16 | 2021-09-29 | イプセン バイオファーム リミティド | 安定化カンプトテシン医薬組成物 |
| MA45517B1 (fr) | 2015-10-23 | 2021-04-30 | Merus Nv | Molécules de liaison inhibant la croissance de cancer |
| WO2017086419A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 液性免疫応答の増強方法 |
| JP6931329B2 (ja) | 2015-11-18 | 2021-09-01 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法 |
| KR101746152B1 (ko) | 2015-12-07 | 2017-06-13 | 주식회사 이수앱지스 | ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도 |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| CN108884142A (zh) | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | 用于癌症治疗的工程化trail |
| MX2018015853A (es) | 2016-07-14 | 2019-08-21 | Genmab As | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). |
| SG11201903615WA (en) | 2016-11-02 | 2019-05-30 | Ipsen Biopharm Ltd | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| BR112019012847A2 (pt) | 2017-01-17 | 2019-12-10 | Daiichi Sankyo Co Ltd | anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor. |
| EP4527854A3 (en) | 2017-03-09 | 2025-06-25 | Genmab A/S | Antibodies against pd-l1 |
| MX2019011660A (es) | 2017-03-31 | 2019-11-18 | Merus Nv | Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1). |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| BR112019024230A2 (pt) | 2017-05-17 | 2020-06-09 | Merus N.V. | combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama |
| EP3642343B1 (en) | 2017-06-20 | 2021-12-08 | Albumedix Ltd. | Improved protein expression strains |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| AU2018312816B2 (en) | 2017-08-09 | 2021-05-27 | Merus N.V. | Antibodies that bind EGFR and cMET |
| JP7366745B2 (ja) | 2017-08-31 | 2023-10-23 | 第一三共株式会社 | 抗体－薬物コンジュゲートの改良製造方法 |
| CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
| EP3710483A4 (en) * | 2017-11-16 | 2021-10-20 | XL-protein GmbH | PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY |
| PT3794042T (pt) | 2018-05-18 | 2024-06-14 | Daiichi Sankyo Co Ltd | Conjugado anticorpo-fármaco anti-muc1-exatecano |
| AU2019311596A1 (en) | 2018-07-27 | 2021-01-28 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
| WO2020027100A1 (ja) | 2018-07-31 | 2020-02-06 | 第一三共株式会社 | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 |
| MX2021003234A (es) | 2018-09-19 | 2021-07-16 | Lava Therapeutics N V | Inmunoglobulina de la molecula cd1d de acción dual. |
| CN113454111A (zh) | 2018-11-06 | 2021-09-28 | 健玛保 | 抗体配制剂 |
| CN109627337B (zh) * | 2018-12-29 | 2023-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗prlr的单克隆抗体及其制备方法和应用 |
| BR112021015238A8 (pt) | 2019-02-01 | 2022-08-16 | Lava Therapeutics B V | Novos anticorpos de ligação a cd40 |
| NL2022494B1 (en) | 2019-02-01 | 2020-08-19 | Lava Therapeutics B V | Novel CD40-binding antibodies |
| EP3930687A4 (en) | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| WO2020197943A1 (en) * | 2019-03-26 | 2020-10-01 | Shimadzu Corporation | Photoimmunotherapy and pharmaceutical agent used therefor |
| WO2020237305A1 (en) * | 2019-05-27 | 2020-12-03 | Baker Heart and Diabetes Institute | Binding proteins comprising the extracellular domain of cd39 and methods of treating or preventing neurological diseases |
| EP3792283A1 (en) | 2019-09-16 | 2021-03-17 | Lava Therapeutics B.V. | Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies |
| WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| FI3865155T3 (fi) * | 2020-02-13 | 2023-01-13 | Menetelmä vasta-aineen kohdespesifiseksi modifioimiseksi | |
| KR20220154757A (ko) | 2020-03-18 | 2022-11-22 | 젠맵 에이/에스 | B7h4에 결합하는 항체 |
| WO2021205183A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Polypeptide |
| MX2022013797A (es) | 2020-05-08 | 2022-11-30 | Genmab As | Anticuerpos biespecificos contra cd3 y cd20. |
| GB202007441D0 (en) | 2020-05-19 | 2020-07-01 | Autolus Ltd | Polypeptide |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| WO2022029011A1 (en) | 2020-08-06 | 2022-02-10 | BioNTech SE | Binding agents for coronavirus s protein |
| JP2023541860A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| EP4210746A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| CN116829192A (zh) * | 2020-11-10 | 2023-09-29 | 纽约大学 | 大型胞饮作用选择性单体-药物缀合物 |
| CA3200826A1 (en) | 2020-12-10 | 2022-06-16 | Paul Willem Henri Ida PARREN | Antibodies that bind gamma-delta t cell receptors |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CA3209454A1 (en) | 2021-02-26 | 2022-09-01 | Robertus Cornelis ROOVERS | Antibodies that bind cd123 and gamma-delta t cell receptors |
| BR112023021089A2 (pt) | 2021-05-07 | 2023-12-12 | Genmab As | Composição farmacêutica, método para tratar uma doença, método para tratar câncer em um indivíduo, uso da composição farmacêutica, forma de dosagem unitária, kit de partes, e, método para preparar uma composição farmacêutica |
| IL309319A (en) | 2021-06-21 | 2024-02-01 | Genmab As | Combined dosage regimen CD137 and PD-L1 binding agents |
| WO2023278786A1 (en) * | 2021-06-30 | 2023-01-05 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for targeted delivery of growth factors to the glomerulus |
| TW202328193A (zh) | 2021-09-13 | 2023-07-16 | 美商健生生物科技公司 | 用於治療癌症的CD33 x Vδ2多特異性抗體 |
| AU2022361691A1 (en) | 2021-10-08 | 2024-03-28 | Genmab A/S | Antibodies binding to cd30 and cd3 |
| WO2023067138A1 (en) | 2021-10-21 | 2023-04-27 | LAVA Therapeutics N.V. | Uses of gamma delta t cell activating antibodies |
| WO2023114861A1 (en) * | 2021-12-15 | 2023-06-22 | The Administrators Of The Tulane Educational Fund | Conjugates, their compositions, and their related methods |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| EP4285926A1 (en) | 2022-05-30 | 2023-12-06 | LAVA Therapeutics N.V. | Combination treatment for chronic lymphocytic leukemia |
| EP4292610A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| EP4292609A1 (en) | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Compositions comprising antibodies that bind gamma-delta t cell receptors |
| NL2032398B1 (en) | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| WO2024200573A1 (en) | 2023-03-27 | 2024-10-03 | LAVA Therapeutics N.V. | Nectin-4 binding agents and methods of use |
| EP4438624A1 (en) | 2023-03-27 | 2024-10-02 | LAVA Therapeutics N.V. | Antibodies that bind nectin-4 and gamma-delta t cell receptors |
| EP4442251A1 (en) | 2023-04-05 | 2024-10-09 | Albumedix Ltd | Formulations and uses thereof |
| CN121240884A (zh) | 2023-04-05 | 2025-12-30 | 根马布股份公司 | 包含与cd30和cd3结合的抗体的药用组合物 |
| AR133071A1 (es) | 2023-06-30 | 2025-08-20 | Genmab As | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 |
| WO2025012118A2 (en) | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| TW202519261A (zh) | 2023-07-27 | 2025-05-16 | 荷蘭商拉法醫療公司 | 用於治療癌症之結合γ-δ T細胞受體之抗體 |
| CN119816522B (zh) * | 2023-08-18 | 2025-06-24 | 上海美雅珂生物技术有限责任公司 | 5t4抗体药物偶联物及其应用 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025158071A1 (en) | 2024-01-26 | 2025-07-31 | Sartorius Albumedix Limited | Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction |
| CN118955647A (zh) * | 2024-07-31 | 2024-11-15 | 西安交通大学医学院第一附属医院 | Mdm2/mdmx抑制肽、组合物及制备方法与应用 |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6009A (en) * | 1849-01-09 | Improvement in machines for gathering pea-vines | ||
| US5800815A (en) | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
| US4450103A (en) | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5753627A (en) | 1988-12-05 | 1998-05-19 | Novartis Ag | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5705363A (en) | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| DK0573551T3 (da) | 1991-02-27 | 2003-08-04 | Micromet Ag | Serinrige peptidlinkere |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| FR2686620B1 (fr) | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| ATE182625T1 (de) | 1993-01-12 | 1999-08-15 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
| CN1074243A (zh) | 1993-02-06 | 1993-07-14 | 北京中化生物技术研究所 | 白介素6-白介素2融合蛋白及其制法和用途 |
| US5780594A (en) | 1993-03-01 | 1998-07-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Biologically active protein fragments containing specific binding regions of serum albumin or related proteins |
| US5928904A (en) | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5914110A (en) | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| US5658763A (en) | 1993-10-25 | 1997-08-19 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
| US5936065A (en) | 1993-12-06 | 1999-08-10 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5821231A (en) | 1993-12-06 | 1998-10-13 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using same |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US8715645B2 (en) | 1994-05-27 | 2014-05-06 | The Regents Of The University Of Colorado | Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| EP0873363B1 (en) | 1995-06-14 | 2010-10-06 | The Regents of The University of California | High affinity human antibodies to tumor antigens |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6686350B1 (en) | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
| US6423512B1 (en) | 1996-07-26 | 2002-07-23 | Novartis Ag | Fusion polypeptides |
| MY120425A (en) | 1996-07-26 | 2005-10-31 | Novartis Ag | Fusion polypeptides |
| JP2002505574A (ja) | 1997-04-30 | 2002-02-19 | エンゾン，インコーポレイテッド | ポリアルキレンオキシド修飾された単鎖ポリペプチド |
| US6191269B1 (en) | 1997-05-30 | 2001-02-20 | The Regents Of The University Of California | Selective induction of cell death by delivery of amino-terminal interleukin-1-α pro-piece polypeptide |
| ATE249421T1 (de) | 1997-06-23 | 2003-09-15 | Tanabe Seiyaku Co | Inhibitoren der alpha4-beta1 vermittelten zelladhäsion |
| US6229011B1 (en) | 1997-08-22 | 2001-05-08 | Hoffman-La Roche Inc. | N-aroylphenylalanine derivative VCAM-1 inhibitors |
| US6455550B1 (en) | 1997-08-22 | 2002-09-24 | Hoffmann-La Roche Inc. | N-alkanoylphenylalanine derivatives |
| US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
| US6171809B1 (en) | 1998-01-29 | 2001-01-09 | Packard Instrument Company | Method and compositions for detecting luciferase biological samples |
| CA2325346A1 (en) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
| GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
| PL198189B1 (pl) | 1998-05-28 | 2008-06-30 | Biogen Idec Ma | (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| US6685617B1 (en) | 1998-06-23 | 2004-02-03 | Pharmacia & Upjohn Company | Inhibitors of α4β1 mediated cell adhesion |
| US6355678B1 (en) | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| TR200101086T2 (tr) | 1998-10-16 | 2001-08-21 | Biogen, Inc. | Interferon beta-1A'nın polimer birleşikleri ve kullanımları. |
| US6333396B1 (en) | 1998-10-20 | 2001-12-25 | Enzon, Inc. | Method for targeted delivery of nucleic acids |
| JP3180906B2 (ja) | 1998-11-12 | 2001-07-03 | 日本電気株式会社 | 磁気抵抗効果型複合ヘッドの製造方法 |
| CN1213025C (zh) | 1999-02-18 | 2005-08-03 | 霍夫曼-拉罗奇有限公司 | 硫代酰胺衍生物 |
| US8236159B2 (en) * | 1999-04-13 | 2012-08-07 | Applied Materials Inc. | Electrolytic process using cation permeable barrier |
| US6265572B1 (en) | 1999-04-20 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents |
| US7534866B2 (en) | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| US6756378B2 (en) | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
| US7067313B1 (en) | 1999-07-14 | 2006-06-27 | D. Collen Research Foundation | Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| WO2001012186A1 (en) | 1999-08-13 | 2001-02-22 | Biogen, Inc. | Cell adhesion inhibitors |
| US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
| EP1094110A1 (en) | 1999-10-21 | 2001-04-25 | Leadd B.V. | Apoptosis inducing proteinaceous substance |
| ATE355269T1 (de) | 1999-11-18 | 2006-03-15 | Ajinomoto Kk | Phenylalaninderivate |
| US6380387B1 (en) | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
| IL149758A0 (en) | 1999-12-28 | 2002-11-10 | Pfizer Prod Inc | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases |
| US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
| AU2001242743A1 (en) | 2000-03-23 | 2001-10-03 | Ajinomoto Co. Inc. | Novel phenylalanine derivative |
| US20050100991A1 (en) | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| AU2001261735B2 (en) | 2000-05-19 | 2006-09-21 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| GB0027328D0 (en) | 2000-06-23 | 2000-12-27 | Aventis Pharma Inc | Bioengineered vehicles for targeted nucleic acid delivery |
| US6787636B1 (en) | 2000-07-14 | 2004-09-07 | New Century Pharmaceuticals, Inc. | Modified serum albumin with reduced affinity for nickel and copper |
| US20040247565A1 (en) | 2000-07-19 | 2004-12-09 | Chih-Ping Liu | Method of treatment using interferon-tau |
| US7015216B2 (en) | 2000-07-21 | 2006-03-21 | Elan Pharmaceuticals, Inc. | Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors |
| AU2001278986A1 (en) | 2000-07-21 | 2002-02-05 | Elan Pharmaceuticals, Inc. | 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors |
| CA2420040C (en) | 2000-08-18 | 2009-02-03 | Ajinomoto Co., Inc. | New phenylalanine derivatives |
| US20040039040A1 (en) | 2000-09-14 | 2004-02-26 | Toshiya Takahashi | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient |
| AU2001288114B2 (en) | 2000-09-25 | 2006-04-27 | Toray Industries, Inc. | Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| PL364142A1 (en) | 2001-02-22 | 2004-12-13 | Celltech R & D Limited | Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| ES2180416B1 (es) | 2001-03-12 | 2004-06-01 | BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. | Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen. |
| IL159894A0 (en) | 2001-07-17 | 2004-06-20 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins |
| WO2003010135A1 (en) | 2001-07-26 | 2003-02-06 | Ajinomoto Co., Inc. | Novel phenylpropionic acid derivatives |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4452899B2 (ja) | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| ES2425738T3 (es) | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20030166559A1 (en) | 2002-01-04 | 2003-09-04 | Desjarlais John R. | Dominant negative proteins and methods thereof |
| JPWO2003080611A1 (ja) | 2002-03-22 | 2005-07-21 | 東レ株式会社 | スピロ誘導体及びそれを有効成分とする接着分子阻害剤 |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| GB0216571D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
| GB0216568D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
| US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US20040115204A1 (en) | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
| WO2004082640A2 (en) | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
| US7446125B2 (en) | 2003-04-09 | 2008-11-04 | Universidad Del Pais Vasco | Derivatives of nitroproline compounds, processes of manufacture and uses in the treatment of integrin mediated disorders |
| WO2005035719A2 (en) | 2003-10-03 | 2005-04-21 | Board Of Control Of Michigan Technological University | Modified luciferase |
| US7638331B2 (en) | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
| EP2374817B1 (en) | 2004-04-13 | 2017-09-06 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
| KR101201464B1 (ko) | 2004-05-05 | 2012-11-14 | 메리맥 파마슈티컬즈, 인크. | 생물학적 활성을 조정하기 위한 이특이성 결합제 |
| BRPI0511755A (pt) | 2004-06-01 | 2008-01-02 | Domantis Ltd | composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização |
| TW200610754A (en) | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
| US20060018859A1 (en) | 2004-07-16 | 2006-01-26 | Carter Daniel C | Modified human serum albumin with reduced or eliminated affinity to chemical or biological contaminants at Cys 34 |
| US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
| ZA200703478B (en) | 2004-10-05 | 2008-07-30 | Genentech Inc | Therapeutic agents with decreased toxicity |
| EP1838735A2 (en) | 2004-12-31 | 2007-10-03 | Genentech, Inc. | Polypeptides that bind br3 and uses thereof |
| KR20070114765A (ko) | 2005-02-23 | 2007-12-04 | 메리맥 파마슈티컬즈, 인크. | 생물학적 활성을 조절하기 위한 이특이성 결합제 |
| WO2007098106A2 (en) | 2006-02-17 | 2007-08-30 | Pepgen Coporation | Respiratory tract delivery of interferon-tau |
| EP2615108B1 (en) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and thier uses |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2091975A4 (en) | 2006-11-21 | 2013-05-22 | Univ California | ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE |
| WO2008076949A2 (en) * | 2006-12-15 | 2008-06-26 | Concert Pharmaceuticals Inc. | Quinazoline derivatives and methods of treatment |
| NZ589086A (en) | 2008-04-11 | 2012-09-28 | Merrimack Pharmaceuticals Inc | Human serum albumin (HSA) linkers and conjugates thereof |
| EP2318548B1 (en) * | 2008-08-15 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| US8927694B2 (en) * | 2008-11-18 | 2015-01-06 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| BR112012029611A2 (pt) * | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| JP2015502741A (ja) * | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| WO2014036520A1 (en) * | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
-
2009
- 2009-10-14 US US13/130,007 patent/US8927694B2/en not_active Expired - Fee Related
- 2009-10-14 WO PCT/US2009/060721 patent/WO2010059315A1/en not_active Ceased
- 2009-10-14 JP JP2011536365A patent/JP5677972B2/ja not_active Expired - Fee Related
- 2009-10-14 CN CN2009801545099A patent/CN102282168A/zh active Pending
- 2009-10-14 BR BRPI0921586A patent/BRPI0921586A2/pt not_active IP Right Cessation
- 2009-10-14 KR KR1020117014075A patent/KR20110112301A/ko not_active Ceased
-
2010
- 2010-04-09 US US12/757,801 patent/US20110059076A1/en not_active Abandoned
-
2014
- 2014-12-24 US US14/582,719 patent/US20150191545A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/251,158 patent/US20170204192A1/en not_active Abandoned